摘要
目的观察利奈唑胺抗感染治疗肾功能不全患者的血液学毒性。方法使用利奈唑胺注射液0.6 g静脉滴注(每日2次)抗感染治疗的119例患者中,59例显示肾功能不全(肾小球滤过率<90 mL/min, A组),60例肾功能正常(肾小球滤过率≥90 mL/min, B组),比较两组给药后血液学毒性指标(血小板减少和贫血)及停药后血小板计数和血红蛋白恢复情况,观察给药后患者不良反应发生情况。结果 A组给药后血小板减少发生率高于B组(47.5%vs.18.3%)(P<0.05),而贫血发生率与B组相仿(10.2%vs.5.0%)(P>0.05)。A组给药后出现血小板减少的时间短于B组[(5.5±3.6) d vs.(10.1±4.7) d](P<0.05),而出现贫血的时间与B组相仿[(4.5±1.3) d vs.(5.5±3.0) d](P>0.05)。A组停药后血小板计数[(5.6±1.4) dvs.(7.8±3.3) d]和血红蛋白[(4.2±2.3) d vs.(3.8±1.4) d]恢复时间与B组相仿(P>0.05)。A组总不良反应发生率高于B组(57.6%vs. 28.3%)(P<0.05)。结论肾功能不全患者使用利奈唑胺抗感染治疗易发生血液学毒性,且药物不良反应发生率高,临床应积极监测患者的血液学相关指标。
Objective To observe the hematological toxicity of anti-infection treatment of linezolid in the patients with renal insufficiency.Methods A total of 119 patients was treated with lineczolid injection 0.6 g intravenously twice per day,of whom 59 cases were with renal insufficiency(glomerular filtration rate<90 mL/min,group A)and 60 cases were with normal renal function(glomerular filtration rate≥90 mL/min,group B).Hematological toxicity indicators(thrombocytopenia and anemia)during treatment,and the recovery of platelet count and hemoglobin after withdrawal were compared between the two groups.The incidence of adverse responses after administration was observed.Results After administration,the incidence of thrombocytopenia in group A was higher than that in group B(47.5%vs.18.3%)(P<0.05),which of anemia in groups of A and B was similar(10.2%vs.5.0%)(P>0.05).The onset time of thrombocytopenia in group A was shorter than that in group B[(5.5±3.6)days vs.(10.1±4.7)days](P<0.05),which of anemia in groups of A and B was similar[(4.5±1.3)days vs.(5.5±3.0)days](P>0.05).After treatment,the recovery time of platelet count[(5.6±1.4)days vs.(7.8±3.3)days]and hemoglobin[(4.2±2.3)days vs.(3.8±1.4)days]in groups of A and B was similar(P>0.05).The incidence of total adverse responses in group A was higher than that in group B(57.6%vs.28.3%)(P<0.05).Conclusion Anti-infective treatment with linezolid in the patients with renal insufficiency is prone to produce haematological toxicity with a higher incidence of adverse drug responses.Therefore,relevant haematological indicators should be actively monitored clinically in the patients undergoing linezolid treatment.
作者
陈晓孩
黄春燕
张伟
吴淑娟
王晖
蔡跃飘
CHEN Xiaohai;HUANG Chunyan;ZHANG Wei(Department of Pharmacy,Third Affiliated Hospital,Wenzhou Medical University,Ruian 325200,CHINA)
出处
《江苏医药》
CAS
2021年第6期588-590,594,共4页
Jiangsu Medical Journal
关键词
利奈唑胺
肾功能不全
血液学毒性
Linezolid
Renal insufficiency
Hematological toxicity
